Salarius Pharmaceuticals, Inc. (SLRX) Revenue History
Annual and quarterly revenue from 2015 to present
SLRX Revenue Over Time (2015–2024)
SLRX Revenue Growth History
3 of 5 years with positive growth- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- +26.1%
- FY2018 revenue growth
- -34.2%
- FY2019 revenue growth
- +313.4%
- FY2020 revenue growth
- +51.0%
- FY2021 revenue growth
- -100.0%
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
| Q1 2024 | $0 | — |
| Q4 2023 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2020)
SLRX's revenue distribution by segment and geography for fiscal year 2020
By Product/Segment
SLRX Revenue Analysis (2015–2024)
Current Revenue & Growth
As of June 23, 2026, Salarius Pharmaceuticals, Inc. (SLRX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue
Historical Growth Trajectory
SLRX's historical revenue data shows various trends over time. Salarius Pharmaceuticals, Inc.'s highest annual revenue of $5.2 million was recorded in 2020.
Revenue by Segment
SLRX's revenue is primarily driven by Grant, Castration-Resistant Prostate Study (100%). With over half of revenue concentrated in Grant, Castration-Resistant Prostate Study, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including KROS (-84.5% YoY), TPVG, and AGEN (+24.5% YoY). Compare SLRX vs KROS →
SLRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SLRXCurrent | $0 | - | - | - | |
 KROS | $244M | -84.5% | - | 28.9% | |
 TPVG | $97M | - | - | 77.9% | |
 AGEN | $114M | +24.5% | +5.3% | -18.0% |
SLRX Historical Revenue Data (2015–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-5,734,316 | - |
| 2023 | $0 | - | $0 | - | $-12,894,944 | - |
| 2022 | $0 | - | $0 | - | $-31,841,140 | - |
| 2021 | $0 | -100.0% | $0 | - | $-12,812,931 | - |
| 2020 | $5.2M | +51.0% | $5.2M | 100.0% | $-7,786,345 | -148.8% |
| 2019 | $3.5M | +313.4% | $3.5M | 100.0% | $-8,265,077 | -238.5% |
| 2018 | $838K | -34.2% | $407K | 48.6% | $-22,074,223 | -2633.7% |
| 2017 | $1.3M | +26.1% | $768K | 60.3% | $-34,725,626 | -2724.6% |
| 2016 | $1.0M | - | $348K | 34.4% | $-39,886,232 | -3946.5% |
| 2015 | $0 | - | $-49,881 | - | $-29,213,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SLRX — Frequently Asked Questions
Quick answers to the most common questions about buying SLRX stock.
Is SLRX's revenue growth accelerating or slowing?
SLRX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is SLRX's revenue history from 2015 to 2026?
Salarius Pharmaceuticals, Inc. (SLRX) revenue history spans 2015 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is SLRX's long-term revenue growth rate (CAGR)?
Salarius Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for SLRX.
Why does SLRX's quarterly revenue fluctuate?
SLRX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Salarius Pharmaceuticals, Inc.'s revenue data from 2015 to 2026 shows full historical quarterly detail on this page.
How is SLRX's revenue distributed by segment?
SLRX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does SLRX's revenue compare to industry peers?
Salarius Pharmaceuticals, Inc. (SLRX) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.